Busulfan

"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Descriptor ID	D002066
MeSH Number(s)	D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
Concept/Terms	Busulfan Busulfan Busulphan Busulfan Wellcome Busulfan Wellcome Wellcome, Busulfan Busulfex Busulfex Myleran Myleran Myléran Myelosan Myelosan Mylecytan Mylecytan n-Butane-1,3-di(methylsulfonate) n-Butane-1,3-di(methylsulfonate) Glyzophrol Glyzophrol

Below are MeSH descriptors whose meaning is more general than "Busulfan".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Alcohols [D02.033]
Glycols [D02.033.455]
Butylene Glycols [D02.033.455.125]
Busulfan [D02.033.455.125.125]
Hydrocarbons [D02.455]
Hydrocarbons, Acyclic [D02.455.326]
Alkanes [D02.455.326.146]
Alkanesulfonic Acids [D02.455.326.146.100]
Alkanesulfonates [D02.455.326.146.100.050]
Mesylates [D02.455.326.146.100.050.500]
Busulfan [D02.455.326.146.100.050.500.100]
Sulfur Compounds [D02.886]
Sulfur Acids [D02.886.645]
Sulfonic Acids [D02.886.645.600]
Alkanesulfonic Acids [D02.886.645.600.055]
Alkanesulfonates [D02.886.645.600.055.050]
Mesylates [D02.886.645.600.055.050.510]
Busulfan [D02.886.645.600.055.050.510.100]

Below are MeSH descriptors whose meaning is related to "Busulfan".

Below are MeSH descriptors whose meaning is more specific than "Busulfan".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Busulfan" by people in this website by year, and whether "Busulfan" was a major or minor topic of these publications.

Bar chart showing 6 publications over 5 distinct years, with a maximum of 2 publications in 1996

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
2006	1	0	1
2015	0	1	1
2018	0	1	1
2021	0	1	1

Below are the most recent publications written about "Busulfan" by people in Profiles.

Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545.

View in: PubMed
Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.

View in: PubMed
Geyer MB, Radhakrishnan K, Giller R, Umegaki N, Harel S, Kiuru M, Morel KD, LeBoeuf N, Kandel J, Bruckner A, Fabricatore S, Chen M, Woodley D, McGrath J, Baxter-Lowe L, Uitto J, Christiano AM, Cairo MS. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. J Pediatr. 2015 Sep; 167(3):765-9.e1.

View in: PubMed
Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, Nance AG, Tilden AB, Carabasi MH. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006 Jul; 12(7):770-7.

View in: PubMed
Styler MJ, Crilley P, Biggs J, Moul J, Copelan E, Topolsky D, Avalos B, Penza S, Sabol P, Downs K, Szer J, Brodsky I, Marks DI. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant. 1996 Jul; 18(1):171-6.

View in: PubMed
Topolsky D, Crilley P, Styler MJ, Bulova S, Brodsky I, Marks DI. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant. 1996 Apr; 17(4):549-54.

View in: PubMed
Crilley P, Topolsky D, Styler MJ, Bernstein E, Resnick K, Mullaney R, Bulova S, Brodsky I, Marks DI. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone Marrow Transplant. 1995 Mar; 15(3):361-5.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement